|Bid||9.65 x 800|
|Ask||9.70 x 1300|
|Day's range||9.60 - 9.75|
|52-week range||9.00 - 26.10|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Paratek (PRTK) delivered earnings and revenue surprises of -1.08% and -60.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Boston-based company said it had a loss of 94 cents per share. The results missed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss ...
The Boston-based company said it had a loss of 91 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...
Given the large number of biotech firms, the task of selecting stocks with possibilities to beat estimates could appear daunting. We pick five biotech stocks likely to deliver an earnings surprise.
Paratek Pharmaceuticals (PRTK) is seeking approval for its antibiotic candidate, omadacycline, for the treatment of CABP and ABSSSI in the United States.
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ
More deals are expected to be signed in the biotech space, now that the tax reform bill allows companies to repatriate cash pilling up overseas.
Vertex (VRTX) receives extension of the marketing application for Orkambi to include use in children with CF who have two copies of the F508del mutation from European Commission.
Allergan (AGN) and partner Paratek announces that its new drug application for Seysara has been accepted for review by the FDA for moderate to severe acne vulgaris.
The Boston-based company said it had a loss of 77 cents per share. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss ...
Paratek Corp., Nabriva Therapeutics, and Cempra all appear on course to bring new antibiotics to market soon. But which could be the best bet for your portfolio now?